Target intelligence / Profile preview

Bifidobacterium carbohydrate transporter (None established; sometimes referenced generally as "ABC transporter" or "PEP-PTS" in literature, but these are system-wide abbreviations and not unique to bifidobacteria)

Target
None established; sometimes referenced generally as "ABC transporter" or "PEP-PTS" in literature, but these are system-wide abbreviations and not unique to bifidobacteria
Molecular classification
Transporter, ATP-binding cassette (ABC) transporter, Major facilitator superfamily (MFS) transporter, Phosphoenolpyruvate-phosphotransferase system (PEP-PTS), Symporter
01

Overview

Bifidobacterium carbohydrate transporters are membrane proteins that enable these gut commensal bacteria to efficiently internalize dietary and host-derived carbohydrates such as human milk oligosaccharides, mucin glycans, and plant fibers. The major types include ATP-binding cassette (ABC) transporters, which hydrolyze ATP to import oligosaccharides and monosaccharides, and phosphoenolpyruvate-phosphotransferase systems (PEP-PTS), which couple the transport and phosphorylation of various sugars. These transporters are highly specialized, species- and substrate-specific, and under complex transcriptional regulation in response to nutrient availability. Their functional adaptation facilitates colonization, competitive survival, and metabolic contribution of bifidobacteria to infant gut development and adult host health. Therapeutically, they are the basis for prebiotic selection and strategies aiming to boost beneficial gut bacteria, though are not direct drug targets.

Other names
Bifidobacterial ABC transporterBifidobacterial PEP-PTS systemCarbohydrate uptake transporterSugar transporter
02

Mechanism of action

For prebiotics: Competitive substrate utilization—prebiotics are selectively internalized by bifidobacterial carbohydrate transporters, enhancing the abundance and activity of bifidobacteria in the gut microbiome and thereby promoting gut health and pathogen exclusion.

03

Biological functions

Carbohydrate uptake (internalization of dietary and host-derived sugars)Glycan utilization (e.g., human milk oligosaccharides, mucin glycans, plant oligosaccharides)Nutrient sensing and metabolic regulation (catabolite repression, signal transduction)Symbiotic function in human gut microbiota, colonization, and metabolic adaptation
04

Disease associations

Infection (as a beneficial actor—bifidobacteria counteract gut pathogens by competitive nutrient uptake, contributing to gut health)Other: Gut dysbiosis, metabolic diseases (the composition and carbohydrate metabolism of bifidobacteria alter host metabolic states; potential in regulating obesity, allergies, and inflammatory bowel disease due to prebiotic/preferential substrate competitive behaviors)
05

Safety considerations

Few direct safety concerns for transporter-targeted strategies, as bifidobacteria are commensal microbes. Main challenge: manipulating transporter activity may unpredictably alter microbiome dynamics or cross-feed undesirable species; excessive prebiotic supplementation can lead to GI symptoms
06

Interacting drugs

No approved drugs directly targeting bifidobacterial carbohydrate transporters.

1 more in the full profile.

07

Biomarkers

Bifidobacterium abundance (often used as a biomarker for gut health, indirectly reflects transporter activity)Levels of short-chain fatty acids (SCFA), acetate, and lactate in stool (metabolic end-products of bifidobacterial carbohydrate metabolism, indicating transporter-functional carbohydrate uptake)

Beyond the preview

Go deeper on Bifidobacterium carbohydrate transporter (None established; sometimes referenced generally as "ABC transporter" or "PEP-PTS" in literature, but these are system-wide abbreviations and not unique to bifidobacteria).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium carbohydrate transporter (None established; sometimes referenced generally as "ABC transporter" or "PEP-PTS" in literature, but these are system-wide abbreviations and not unique to bifidobacteria).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call